ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2011) 26 P562

Metabolic syndrome and the effect of testosteron treatment in young men with congenital hypogonadotrophic hypogonadism

A Sonmez1, C Haymana1,2, E Bolu1, A Aydogdu1, S Tapan1,3, M Serdar1,3, B Altun1,2, C Barcin1,4, A Taslipinar1, C Meric1, G Uckaya1 & M Kutlu1

1Gulhane School of Medicine Department of Endocrinology and Metabolism, Ankara, Turkey; 2Gulhane School of Medicine Department of Internal Medicine, Ankara, Turkey; 3Gulhane School of Medicine Department of Biochemistry, Ankara, Turkey; 4Gulhane School of Medicine Department of Cardiology, Ankara, Turkey.

Objective: The relationship between metabolic syndrome (MS) and hypogonadism has always been investigated in study groups confounded with aging, obesity or chronic metabolic disorders. So far there has been no data about the presence of MS in young hypogonadal patients. Also there is controversial data about the metabolic effects of testosteron replacement therapy. We investigated the frequency of MS in treatment naïve, young men with congenital hypogonadal hypogonadism (CHH). We also searched for the effect of testosteron replacement on the metabolic profiles of this specific patient group.

Design: Retrospective analysis

Methods: A total number of 332 patients (age 21.68±2.09 years) were enrolled. The control group was the 395 age and body mass index (BMI) matched healthy young men (age 21.39±1.49 years). Standard regimen of testosteron esters (250 mg/3 weeks) were given to 208 patients.

Results: MS was more prevalent in CHH (P<0.001) according to healthy controls. The patients had higher arterial blood pressure, waist circumference (WC), triglyceride (P<0.001 for all), fasting glucose (P=0.02), insulin (P=0.004), HOMA-IR (P=0.002) and lower HDL cholesterol (P<0.001) levels. With a mean follow-up period of 5.63±2.6 months, the BMI, WC (P<0.001 for both), systolic blood pressures (P=0.002) and triglyceride levels (P=0.04) were increased and the total and HDL cholesterol levels were decreased (P=0.02 and P<0.001 respectively).

Conclusions: This study shows increased prevalence of MS and unfavorable effects of testosteron replacement in young patients with CHH. Long term follow up studies are warranted to investigate the cardiovascular safety of testosteron treatment in this specific population.